Elicio Therapeutics Inc. (ELTX)
Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers.
It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers.
The company is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Robert T. Connelly |
Contact Details
Address: 451 D Street Boston, Massachusetts United States | |
| Website | https://elicio.com |
Stock Details
| Ticker Symbol | ELTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001555192 |
| CUSIP Number | 28657F103 |
| ISIN Number | US28657F1030 |
| Employer ID | 45-2966790 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert T. Connelly | Chief Executive Officer, President & Director |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder & Independent Director |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research & Development and Chief Medical Officer |
| Dr. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Strategy & Financial Officer and Treasurer |
| Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics |
| Esther Welkowsky | Senior Vice President of Clinical Development |
| Joy Seymour | Vice President & Head of Regulatory Affairs |
| Megan C. Filoon | General Counsel, Secretary & Compliance Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2025 | 4 | Filing |
| Apr 09, 2025 | ARS | Filing |
| Apr 09, 2025 | DEF 14A | Filing |
| Apr 02, 2025 | 3 | Filing |
| Mar 31, 2025 | S-8 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 07, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 07, 2025 | 4 | Filing |